By Colin Kellaher

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Wednesday said the U.S. Food and Drug Administration approved a six-month version of its antipsychotic Invega.

The drug maker said Invega Hafyera is the first FDA-approved twice-yearly injectable for the treatment of schizophrenia in adults.

Janssen said patients must first be treated with its Invega Sustenna one-month drug for at least four months or its Invega Trinza three-month dose at least once before switching to the new six-month Invega Hafyera.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 01, 2021 08:45 ET (12:45 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Johnson and Johnson.